Developing life-saving therapies for blood cancer patients

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life‑saving therapies for patients with late stage blood cancers and related disorders in need of a transplant, an area of significant unmet medical need.

ATIR™ is Kiadis Pharma’s lead product in development and enables partially matched stem cells from family members (haploidentical donors) to be used in reconstituting the immune system of blood cancer patients after a bone marrow transplantation without eliciting severe or life threatening Graft-versus-Host-Disease (GvHD).

The Company is currently sponsoring a multi‑center Phase II clinical trial for ATIR™ and is collaborating with renowned centers in Europe and North America.








Click to download the Company Fact Sheet which provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.



News Digest



Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, will present interim results of Kiadis Pharma’s ongoing international multi-center Phase II study at the 2014 annual meeting of ASH (American Society of Hematology). The study investigates the safety and efficacy of adding ATIR™ to a T-cell depleted haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). Presentation of the interim results will be held on Monday, December 8, 2014 and a copy of the abstract can be found here.

ATIR™ has recently been awarded a third Orphan Drug Designation, for the treatment of AML in the European Union.

 



Advanced Therapies Investor Day



Watch the company presentation by Manfred Rüdiger at the Advanced Therapies Investor Day held on November 13, 2014 in London, UK


 

Upcoming Conferences



Haploidentical Transplantation Forum
December 4, 2014 - San Francisco, USA

American Society of Hematology (ASH) Annual Meeting
December 6-9, 2014 - San Francisco, USA

JP Morgan Annual Healthcare Conference
January 12-16, 2015 - San Francisco, USA

Phacilitate Cell & Gene Therapy Forum
January 26-28, 2015 - Washington DC, USA

European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
March 22-25, 2015 - Istanbul, Turkey